Skip to main content
Grand Pharmaceutical Group Limited logo

Grand Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 512 ISIN · BMG210A71016 LEI · 8945001XW4FS15S8Z778 HKEX Manufacturing
Open in API
Filings indexed 1,169 across all filing types
Latest filing 2026-03-20 Earnings Release
Country BM Bermuda
Listing HKEX 512

About Grand Pharmaceutical Group Limited

http://www.grandpharma.cn

Grand Pharmaceutical Group Limited is an international, technology-driven pharmaceutical enterprise specializing in the research, development, manufacture, and sale of innovative healthcare solutions. The company's strategic focus encompasses three primary areas: pharmaceutical technology, nuclear medicine for anti-tumor diagnosis and treatment, and cerebro-cardiovascular precision intervention. Key product lines include anti-tumor and cardiovascular emergency pharmaceutical products, as well as intervention medical devices. The organization maintains a strong commitment to R&D, actively developing next-generation therapies, such as mRNA drugs designed to combat tumors and infections. Additionally, the company provides a range of bio-health products, including amino acid and taurine series.

Recent filings

Filing Released Lang Actions
PROFIT WARNING
Earnings Release Classification · 1% confidence The document is a 'Profit Warning' issued by Grand Pharmaceutical Group Limited. It provides preliminary, unaudited financial expectations for the year ended 31 December 2025, explaining the reasons for the expected decrease in profit compared to the previous year. This type of announcement is a standard regulatory requirement for listed companies to inform the market of significant changes in financial performance before the full annual report is released. It fits the definition of an 'Earnings Release' (ER) as it provides key financial highlights and performance expectations. FY 2025
2026-03-20 English
ANNOUNCEMENT PURSUANT TO RULE 13.18 OF THE LISTING RULES
Capital/Financing Update Classification · 1% confidence The document is an announcement regarding a new facility agreement (loan) entered into by the company. It specifically mentions Rule 13.18 of the Listing Rules, which requires disclosure of loan agreements that include covenants relating to specific performance obligations of the controlling shareholders. This falls under the category of company financing and capital structure updates.
2026-03-19 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 1% confidence The document is a short announcement (1398 characters) from Grand Pharmaceutical Group Limited regarding the scheduling of a board meeting to approve annual results and dividends. It does not contain the actual financial report, but rather serves as a notification of the upcoming publication of results. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2026-03-17 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2026
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and public float. As it is a recurring regulatory filing regarding share capital and securities status that does not fit into specific categories like 'Transaction in Own Shares' (which would be a specific buyback report) or 'Share Issue' (which would be a specific announcement of a new issuance), it is best classified as a general regulatory filing.
2026-03-02 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2026
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Stock Exchange (HKEX). This is a standard regulatory filing required by the HKEX Listing Rules (specifically Rule 13.25A) to report monthly movements in securities, share capital, and public float. Since it does not fit into specific categories like 'Share Issue' (which would be a specific event) or 'Transaction in Own Shares' (which would be a specific buyback report), and it is a recurring regulatory disclosure, it is best classified as a Regulatory Filing (RNS).
2026-02-03 English
SUPPLEMENTAL AND CLARIFICATION ANNOUNCEMENT - CONNECTED TRANSACTION - ACQUISITION OF THE ENTIRE EQUITY INTERESTS IN HEBEI YUANDA JIUFU BIOTECHNOLOGY CO., LTD. AND BAODING JIAHE FINE CHEMICAL CO., LTD
M&A Activity Classification · 1% confidence The document is a 'Supplemental and Clarification Announcement' regarding a previously disclosed 'Connected Transaction' (acquisition of equity interests). It provides detailed valuation methodology, comparable company analysis, and financial justifications for the transaction. This falls under the category of M&A activity (TAR) as it relates to the details of an acquisition, rather than a general regulatory filing or a simple report publication announcement.
2026-02-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.